From the UN World Drug Report 2023 (June 26)"There is a growing...

From the UN World Drug Report 2023 (June 26)

"There is a growing commercial interest in capitalizing on the psychedelic developments. For example, market forecasts for the near future estimate that the market size of ketamine-assisted therapy will be worth over 1 billion dollars and that of MDMA-assisted therapy over 2 billion dollars in the United States. Such economic prospects could lead the industry to lobby for more loosely regulated market policies that maximize profits rather than safeguard public health interests."

We are 7.7% the population of the US. This implies a 232m market within Australia between Ketamine-assisted therapy and MDMA-assisted therapy.

EMD absolutely best positioned to deliver these in a way which emphasises collecting research alongside delivering these therapies to safeguard public health interests.

Not capitulating =).

https://www.unodc.org/res/WDR-2023/WDR23_Exsum_fin_SP.pdf